RT Journal Article SR Electronic T1 Estimated durations of asymptomatic, symptomatic, and care-seeking phases of tuberculosis disease JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.17.21253823 DO 10.1101/2021.03.17.21253823 A1 Ku, Chu-Chang A1 MacPherson, Peter A1 Khundi, McEwen A1 Nzawa, Rebecca A1 Feasey, Helena RA. A1 Nliwasa, Marriott A1 Horton, Katherine C. A1 Corbett, Elizabeth L. A1 Dodd, Peter J. YR 2021 UL http://medrxiv.org/content/early/2021/04/04/2021.03.17.21253823.abstract AB Ratios of bacteriologically-positive tuberculosis prevalence to notification rates are used to characterise typical durations of tuberculosis disease, but have not accounted for asymptomatic periods prior to care-seeking. We developed novel statistical models to estimate progression from initial bacteriological-positivity including smear conversion, symptom onset and initial care-seeking and fitted them to tuberculosis prevalence survey and notification data (one subnational and 11 national datasets) within a Bayesian framework. Asymptomatic tuberculosis duration was in the range 4 – 8 months for African countries; three countries in Asia showed longer durations of > 1 year. Care-seeking typically began half-way between symptom onset and notification. Our method also estimated smear progression rates and case-detection ratios. We found evidence for higher case-detection ratios and much shorter durations of tuberculosis for people living with HIV. To eradicate tuberculosis transmission, greater gains may be achieved by proactively screening people without symptoms through active case finding interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study is an analysis based on secondary data.Funding StatementThis work was supported by the Wellcome Trust (206575/Z/17/Z to PM, 200901/Z/16/Z to ELC) and the UK MRC (MR/P022081/1 to PJD). This UK funded award (PJD) is part of the EDCTP2 programme supported by the European Union. KCH is supported by the European Research Council (757699) and UK FCDO (Leaving no-one behind: transforming gendered pathways to health for TB). This research has been partially funded by UK aid from the UK government (to KCH); however the views expressed do not necessarily reflect the UK government's official policies.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Blantyre, Malawi TB prevalence survey received ethical approval from the College of Medicine, University of Malawi, and from London School of Hygiene and Tropical Medicine. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available as supplementary dataset and a compressed version can be download from the project GitHub repo. https://github.com/TimeWz667/AsymTB.git